Gossamer Bio, Inc. filed a Form S-3 registration statement with the SEC on November 16, 2026, covering the proposed resale of up to 1,697,363 shares of common stock issuable upon the exercise of warrants held by selling securityholders.
Key Highlights
- Shares registered: Up to 1,697,363 shares of common stock, par value $0.0001 per share, issuable upon exercise of warrants.
- Warrant origin: Warrants were issued to eligible holders of the company's outstanding 5.00% Convertible Senior Notes due 2027 in connection with an exchange offer, with early settlement occurring on June 4, 2026.
- No company proceeds from resales: According to the filing, the company will not receive any proceeds from the sale or other disposition of common stock by the selling securityholders.
- Potential cash exercise proceeds: The company disclosed it will generate proceeds in the event of a cash exercise of some or all of the warrants by the selling securityholders.
- Last reported sale price: On November 15, 2026, the last reported sale price of common stock on the Nasdaq Global Select Market was $10.97 per share.
- Registration expenses: All expenses of registration are being borne by the company; all selling and other expenses incurred by the selling securityholders will be borne by the selling securityholders.
Gossamer Bio Registers Warrant-Backed Shares From June 2026 Exchange Offer
Gossamer Bio, Inc. (NASDAQ:GOSS), a Delaware corporation headquartered in San Diego, California, filed a shelf registration statement on Form S-3 on November 16, 2026. The registration covers the proposed resale or other disposition by identified selling securityholders of up to 1,697,363 shares of common stock issuable upon the exercise of warrants. According to the filing, those warrants were issued to eligible holders of the company's outstanding 5.00% Convertible Senior Notes due 2027 in connection with an exchange offer, the early settlement of which occurred on June 4, 2026.
The company disclosed that it is not selling any shares of common stock under this prospectus and will not receive any of the proceeds from resales by the selling securityholders. However, the filing notes that the company will generate proceeds in the event of a cash exercise of some or all of the warrants. The registration statement uses a shelf process under Rule 415, allowing selling securityholders to sell securities from time to time in one or more offerings. The filing states that selling securityholders may dispose of their securities on any national securities exchange, in the over-the-counter market, through privately negotiated transactions, or using a combination of methods, at fixed, prevailing market, varying, or negotiated prices.
The company identified itself as a non-accelerated filer and a smaller reporting company in the registration statement. The filing noted that the registration statement is preliminary and subject to completion, and that the securities may not be sold until the registration statement becomes effective. Faheem Hasnain is identified as President and Chief Executive Officer and agent for service of process.
What Was Disclosed
Gossamer Bio filed a Form S-3 on November 16, 2026, to register up to 1,697,363 shares of common stock for resale by selling securityholders who received warrants through a June 4, 2026 exchange offer involving the company's 5.00% Convertible Senior Notes due 2027.




Please wait processing your request...